Elevated plasma sTIM-3 levels in patients with severe COVID-19 - 09/01/21
Abstract |
Background |
The pathogenesis of coronavirus disease 2019 (COVID-19) is still incompletely understood, but it seems to involve immune activation and immune dysregulation.
Objective |
We examined the parameters of activation of different leukocyte subsets in COVID-19–infected patients in relation to disease severity.
Methods |
We analyzed plasma levels of myeloperoxidase (a marker of neutrophil activation), soluble (s) CD25 (sCD25) and soluble T-cell immunoglobulin mucin domain-3 (sTIM-3) (markers of T-cell activation and exhaustion), and sCD14 and sCD163 (markers of monocyte/macrophage activation) in 39 COVID-19–infected patients at hospital admission and 2 additional times during the first 10 days in relation to their need for intensive care unit (ICU) treatment.
Results |
Our major findings were as follows: (1) severe clinical outcome (ICU treatment) was associated with high plasma levels of sTIM-3 and myeloperoxidase, suggesting activated and potentially exhausted T cells and activated neutrophils, respectively; (2) in contrast, sCD14 and sCD163 showed no association with need for ICU treatment; and (3) levels of sCD25, sTIM-3, and myeloperoxidase were inversely correlated with degree of respiratory failure, as assessed by the ratio of Pao2 to fraction of inspired oxygen, and were positively correlated with the cardiac marker N-terminal pro-B–type natriuretic peptide.
Conclusion |
Our findings suggest that neutrophil activation and, in particular, activated T cells may play an important role in the pathogenesis of COVID-19 infection, suggesting that T-cell–targeted treatment options and downregulation of neutrophil activation could be of importance in this disorder.
El texto completo de este artículo está disponible en PDF.Key words : COVID-19, outcome, T cell, TIM-3, neutrophil
Abbreviations used : COVID-19, eGFR, Fio2, hsCRP, ICU, NT-proBNP, OUH, P/F ratio, s, sTIM-3
Esquema
This project has received a private donation from Vivaldi Invest A/S, which is owned by Jon Stephenson von Tetzchner, and has also received funding from COVID-19 Emergency Call for Proposals: Collaborative and Knowledge-building Projects for the Fight Against Coronavirus Disease (COVID-19) from the Research Council of Norway (grant no. 312780). |
|
Disclosure of potential conflict of interest T. E. Mollnes is a medical advisor for Ra Pharmaceutical, which produces complement inhibitors. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 147 - N° 1
P. 92-98 - janvier 2021 Regresar al númeroBienvenido a EM-consulte, la referencia de los profesionales de la salud.